Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: INCY stock price vs ALNY: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ALNY's multiple
Needs ALNY P/E.
Implied fair value · at INCY's multiple
Needs INCY P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: INCY FY 2025 (ended Dec 31, 2025) · ALNY FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
INCYTE CORPORATION · implied price per share
Bear
-$7.58
Base
-$8.91
Bull
-$10.25
ALNYLAM PHARMACEUTICALS, INC. · implied price per share
Bear
$24.50
Base
$28.82
Bull
$33.15
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
3.83x
3.75x
Net debt / EBITDA
Leverage against operating earnings
9.31x
1.82x
Cash and equivalents
Liquid reserves on the balance sheet
$3.38B
$1.66B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
INCY vs AMGN
GILEAD SCIENCES, INC.
INCY vs GILD
VERTEX PHARMACEUTICALS INC / MA
INCY vs VRTX
REGENERON PHARMACEUTICALS, INC.
INCY vs REGN
BIOGEN INC.
INCY vs BIIB
Moderna, Inc.
INCY vs MRNA
Sarepta Therapeutics, Inc.
INCY vs SRPT
BioNTech SE
INCY vs BNTX
ACADIA PHARMACEUTICALS INC
INCY vs ACAD
$19.78B
$2.96B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
